On Monday, PDL BioPharma Inc (NASDAQ:PDLI)’s shares declined -4.37% to $6.57.
PDL BioPharma Inc (PDLI) declared that the Company will release its first quarter 2015 financial results for the period ended March 31, 2015, on Wednesday, May 6, 2015, after market close. PDL’s administration will host a conference call and webcast that day at 4:30 p.m. Eastern Time to talk about the financial results. A slide presentation regardingthe call will be accessible via the webcast link on the PDL website.
PDL BioPharma, Inc. manages a portfolio of patents and royalty assets in the United States and Europe. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases.
Emerge Energy Services LP (NYSE:EMES)’s shares dropped -1.72% to $38.18.
Emerge Energy Services LP (EMES) declared the appointment of Mr. Jody Tusa as the chief financial officer Emerge Energy Services GP LLC, the general partner of Emerge Energy, effective on May 4, 2015. Mr. Tusa brings more than 35 years of finance experience to his new role, having recently served as CFO of USA Compression Partners, LP. Mr. Tusa replaces Robert Lane, who has resigned for personal reasons. Mr. Lane will remain with Emerge Energy until May 31, 2015 to ensure a smooth transition as Mr. Tusa takes over his duties as Chief Financial Officer.
Emerge Energy Services LP acquires, owns, operates, and develops a portfolio of energy service assets in the United States. The company operates in two segments, Sand and Fuel.
At the end of Monday’s trade, Keryx Biopharmaceuticals (NASDAQ:KERX)‘s shares dipped -3.85% to $10.48.
Keryx Biopharmaceuticals (KERX) declared its financial results for the first quarter ended March 31, 2015.
First Quarter 2015 Business Highlights
- For the quarter ended March 31, 2015, Keryx stated total revenue of about $1.2 million, counting net U.S. Auryxia product revenue and license revenue associated with royalties received on sales of Riona(R) (ferric citrate) in Japan. The Company recognized U.S. product sales based on 1,218 prescriptions filled for Auryxia during the quarter, based on data received from IMS Health and specialty pharmacies that don’t report data to IMS, counting Davita Rx and Fresenius Rx.
- In January 2015, Keryx accomplished an underwritten public offering of common stock, which offered proceeds to the Company of about $118.3 million, net of underwriting discounts and offering expenses. Keryx ended the first quarter with $168.8 million in cash and cash equivalents. Additionally, the Company ended the first quarter with about $27.2 million of inventory on its merged balance sheet, primarily comprising of Auryxia active pharmaceutical ingredient.
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, in addition to treats iron deficiency anemia.
Memorial Production Partners LP (NASDAQ:MEMP), ended its Monday’s trading session with -0.98% loss, and closed at $17.15.
Memorial Production Partners LP (MEMP) declared that the board of directors of its general partner declared a cash distribution of $0.55 per unit for the first quarter of 2015. This distribution represents an annualized amount of $2.20 per unit and will be paid on May 13, 2015 to unitholders of record as of the close of business on May 6, 2015.
Memorial Production Partners LP, through its partner, engages in the acquisition, development, exploitation, and production of oil and natural gas properties.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
